PHARMACEUTICAL DOSAGE FORMS CONTAINING SODIUM-1-[6-(MORPHOLIN-4-YL)PYRIMIDIN-4-YL]-4-(1H-1,2,3-TRIAZOL-1-YL)-1H-PYRAZOL-5-OLATE

The present invention relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for th...

Full description

Saved in:
Bibliographic Details
Main Authors HEIKE NEUMANN, KLAUS BENKE, MICHAEL FORMELL, GABRIELE WINTER
Format Patent
LanguageEnglish
Published 04.04.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for prophylaxis, secondary prophylaxis or treatment of disorders, particularly cardiovascular disorders, heart failure, anaemia, chronic renal disorders and renal insufficiency.
Bibliography:Application Number: MY2016PI701355